Trinity Biotech (TRIB) Payables (2009 - 2025)

Trinity Biotech (TRIB) has reported Payables for 17 consecutive years, with $29.7 million the latest figure, recorded in Q4 2025.

• Quarterly Payables rose 4.44% year-over-year to $29.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.7 million (up 4.44% YoY) and the FY2025 annual result came in at $29.7 million, up 4.44% from the prior year.
• Payables climbed to $29.7 million in Q4 2025 per TRIB's latest filing, from $27.6 million in the prior quarter.
• Over the last five years, Payables for TRIB reached as high as $98.4 million in Q4 2021 and fell as low as $13.3 million in Q4 2023.
• A 5-year average of $24.9 million and a median of $19.8 million in 2021 frame the typical range for Payables.
• Annual changes were most pronounced in 2021 — Payables soared 304.52% — and 2022, when it slumped 82.79%.
• Year by year, Payables stood at $98.4 million in 2021, then sank by 82.79% to $16.9 million in 2022, then retreated by 21.34% to $13.3 million in 2023, then surged by 113.39% to $28.4 million in 2024, then increased by 4.44% to $29.7 million in 2025.
• According to Business Quant data, Payables over the past three periods registered $29.7 million, $27.6 million, and $28.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.